Influence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines

Radiation Oncology

Buelent Polat³  Michael Flentje³  Sebastian Kuger¹  Dirk Vordermark²  Antje Güttler²  Agmal Scherzad⁴  Gisela Wohlleben³ 

[1] Research Unit of Radiation Cytogenetics, Helmholtz–Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany;Department of Radiotherapy, Martin-Luther-University Halle-Wittenberg, Halle, Saale, Germany;Department of Radiation Oncology, University hospital Wuerzburg, Josef-Schneider-Straße 11, Würzburg, 97080, Germany;Department of Oto-Rhino-Laryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, University hospital Wuerzburg, Wuerzburg, Germany

关键词: Glioblastoma multiforme;    Head and neck cancer;    Irradiation;    Hypoxia;    Osteopontin;   

Others  :  1228478
DOI  :  10.1186/s13014-015-0473-x

 received in 2015-05-12, accepted in 2015-07-22,  发布年份 2015

【 摘 要 】

Background

Tumor hypoxia is a known risk factor for reduced response to radiotherapy. The evaluation of noninvasive methods for the detection of hypoxia is therefore of interest. Osteopontin (OPN) has been discussed as an endogenous hypoxia biomarker. It is overexpressed in many cancers and is involved in tumor progression and metastasis.

Methods

To examine the influence of hypoxia and irradiation on osteopontin expression we used different cell lines (head and neck cancer (Cal27 and FaDu) and glioblastoma multiforme (U251 and U87)). Cells were treated with hypoxia for 24 h and were then irradiated with doses of 2 and 8 Gy. Osteopontin expression was analyzed on mRNA level by quantitative real-time RT-PCR (qPCR) and on protein level by western blot. Cell culture supernatants were evaluated for secreted OPN by ELISA.

Results

Hypoxia caused an increase in osteopontin protein expression in all cell lines. In Cal27 a corresponding increase in OPN mRNA expression was observed. In contrast the other cell lines showed a reduced mRNA expression under hypoxic conditions. After irradiation OPN mRNA expression raised slightly in FaDu and U87 cells while it was reduced in U251 and stable in Cal27 cells under normoxia. The combined treatment (hypoxia and irradiation) led to a slight increase of OPN mRNA after 2 Gy in U251 (24 h) and in U87 (24 and 48 h) cell lines falling back to base line after 8 Gy. This effect was not seen in Cal27 or in FaDu cells. Secreted OPN was detected only in the two glioblastoma cell lines with reduced protein levels under hypoxic conditions. Again the combined treatment resulted in a minor increase in OPN secretion 48 hours after irradiation with 8 Gy.

Conclusion

Osteopontin expression is strongly modulated by hypoxia and only to a minor extent by irradiation. Intracellular OPN homeostasis seems to vary considerably between cell lines. This may explain the partly conflicting results concerning response prediction and prognosis in the clinical setting.

【 授权许可】

   
2015 Wohlleben et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26(2):225-239.
• [2]Bittner MI, Grosu AL. Hypoxia in Head and Neck Tumors: Characteristics and Development during Therapy. Frontiers in oncology. 2013; 3:223.
• [3]Thorwarth D, Monnich D, Zips D. Methodological aspects on hypoxia PET acquisition and image processing. Q J Nucl Med Mol Imaging. 2013; 57(3):235-243.
• [4]Halmos GB, Bruine De Bruin L, Langendijk JA, Van Der Laan BF, Pruim J, Steenbakkers RJ. Head and neck tumor hypoxia imaging by 18 F-fluoroazomycin-arabinoside (18 F-FAZA)-PET: a review. Clin Nucl Med. 2014; 39(1):44-48.
• [5]Ostheimer C, Bache M, Guttler A, Kotzsch M, Vordermark D. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor. Strahlenther Onkol. 2014; 190(3):276-282.
• [6]Said HM, Hagemann C, Staab A, Stojic J, Kuhnel S, Vince GH, Flentje M, Roosen K, Vordermark D. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol. 2007; 83(3):398-405.
• [7]Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V et al.. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol. 2008; 9(4):342-351.
• [8]Bache M, Reddemann R, Said HM, Holzhausen HJ, Taubert H, Becker A, Kuhnt T, Hansgen G, Dunst J, Vordermark D. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys. 2006; 66(5):1481-1487.
• [9]Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer. 2008; 8(3):212-226.
• [10]Chong HC, Tan CK, Huang RL, Tan NS. Matricellular proteins: a sticky affair with cancers. J Oncol. 2012; 2012:351089.
• [11]Petrik D, Lavori PW, Cao H, Zhu Y, Wong P, Christofferson E, Kaplan MJ, Pinto HA, Sutphin P, Koong AC et al.. Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol. 2006; 24(33):5291-5297.
• [12]Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le QT, Crowley JJ, Gandara DR. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 2008; 26(29):4771-4776.
• [13]Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 2005; 6(10):757-764.
• [14]Guttler A, Giebler M, Cuno P, Wichmann H, Kessler J, Ostheimer C, Soling A, Strauss C, Illert J, Kappler M et al.. Osteopontin and splice variant expression level in human malignant glioma: radiobiologic effects and prognosis after radiotherapy. Radiother Oncol. 2013; 108(3):535-540.
• [15]Likui W, Hong W, Shuwen Z. Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg. 2010; 14(1):74-81.
• [16]Snitcovsky I, Leitao GM, Pasini FS, Brunialti KC, Mangone FR, Maistro S, De Castro G, Villar RC, Federico MH. Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy. Archives of otolaryngology--head & neck surgery. 2009; 135(8):807-811.
• [17]Lim AM, Rischin D, Fisher R, Cao H, Kwok K, Truong D, McArthur GA, Young RJ, Giaccia A, Peters L et al.. Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial. Clin Cancer Res. 2012; 18(1):301-307.
• [18]Caradec J, Sirab N, Keumeugni C, Moutereau S, Chimingqi M, Matar C, Revaud D, Bah M, Manivet P, Conti M et al.. 'Desperate house genes': the dramatic example of hypoxia. Br J Cancer. 2010; 102(6):1037-1043.
• [19]Zhong H, Simons JW. Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun. 1999; 259(3):523-526.
• [20]Polat B, Wohlleben G, Katzer A, Djuzenova CS, Technau A, Flentje M. Influence of osteopontin silencing on survival and migration of lung cancer cells. Strahlenther Onkol. 2013; 189(1):62-67.
• [21]Hahne JC, Meyer SR, Kranke P, Dietl J, Guckenberger M, Polat B, Honig A. Studies on the role of osteopontin-1 in endometrial cancer cell lines. Strahlenther Onkol. 2013; 189(12):1040-1048.
• [22]Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H, Bache M. Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol. 2010; 5:82. BioMed Central Full Text
• [23]Chang SH, Minai-Tehrani A, Shin JY, Park S, Kim JE, Yu KN, Hong SH, Hong CM, Lee KH, Beck GR et al.. Beclin1-induced Autophagy Abrogates Radioresistance of Lung Cancer Cells by Suppressing Osteopontin. J Radiat Res. 2012; 53(3):422-32.
• [24]Le QT, Kong C, Lavori PW, O'Byrne K, Erler JT, Huang X, Chen Y, Cao H, Tibshirani R, Denko N et al.. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2007; 69(1):167-175.
• [25]Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R et al.. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006; 12(5):1507-1514.
• [26]Bache M, Rot S, Kessler J, Guttler A, Wichmann H, Greither T, Wach S, Taubert H, Soling A, Bilkenroth U et al.. mRNA expression levels of hypoxia-induced and stem cell-associated genes in human glioblastoma. Oncol Rep. 2015; 33(6):3155-3161.
• [27]Hui EP, Sung FL, Yu BK, Wong CS, Ma BB, Lin X, Chan A, Wong WL, Chan AT. Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. Clin Cancer Res. 2008; 14(21):7080-7087.
• [28]Zhu Y, Denhardt DT, Cao H, Sutphin PD, Koong AC, Giaccia AJ, Le QT. Hypoxia upregulates osteopontin expression in NIH-3 T3 cells via a Ras-activated enhancer. Oncogene. 2005; 24(43):6555-6563.